Cargando…
Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
BACKGROUND: Cellular senescence is a key mechanism that drives age-related diseases, but has yet to be targeted therapeutically in humans. Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal cellular senescence-associated disease. Selectively ablating senescent cells using dasatinib plus que...
Autores principales: | Justice, Jamie N., Nambiar, Anoop M., Tchkonia, Tamar, LeBrasseur, Nathan K., Pascual, Rodolfo, Hashmi, Shahrukh K., Prata, Larissa, Masternak, Michal M., Kritchevsky, Stephen B., Musi, Nicolas, Kirkland, James L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412088/ https://www.ncbi.nlm.nih.gov/pubmed/30616998 http://dx.doi.org/10.1016/j.ebiom.2018.12.052 |
Ejemplares similares
-
Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability
por: Nambiar, Anoop, et al.
Publicado: (2023) -
CELLULAR SENESCENCE AS A THERAPEUTIC TARGET FOR GEROSCIENCE-GUIDED CLINICAL TRIALS
por: Justice, Jamie N, et al.
Publicado: (2019) -
Orally-active, clinically-translatable senolytics restore α-Klotho in mice and humans
por: Zhu, Yi, et al.
Publicado: (2022) -
Senolytics: Potential for Alleviating Diabetes and Its Complications
por: Palmer, Allyson K, et al.
Publicado: (2021) -
Senolytic drugs: from discovery to translation
por: Kirkland, J. L., et al.
Publicado: (2020)